TG Therapeutics (TGTX) News Today

TG Therapeutics (NASDAQ:TGTX) Stock Price Down 3.5%

Jupiter Asset Management Ltd. lowered its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 69.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 46,577 shares of the biopharmaceutical company's sto

BNP Paribas Financial Markets reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 70.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,601 shares of the b

TG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High at $23.12

Vanguard Group Inc. increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,670,944 shares of the biopharmaceutical company

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have

TG Therapeutics (NASDAQ:TGTX) Trading Up 3.4%

TG Therapeutics (NASDAQ:TGTX) Trading Down 5.2%

Wellington Management Group LLP boosted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,139,764 shares of the biop

TG Therapeutics (NASDAQ:TGTX) Shares Up 4.4%

Short interest is high and rising in many stocks, setting them up for a squeeze given the proper catalyst. The catalyst for a squeeze could be as simple as Meme stock mania and result in quick gains for savvy investors.

Given the proper catalyst, the short interest in these stocks may lead to a short squeeze. All the market needs is a push and it may come at any time.

Eventide Asset Management LLC acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 439,474 shares of the biopharmaceutical company's stock, valued at

Opaleye Management Inc. lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 17.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,215,000 shares of the bioph

Parkwood LLC reduced its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 85.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,347 shares of the biopharmaceutical company's stock

Lighthouse Investment Partners LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 76,729 shares of the biopharmaceutical company's stock, valued at approximately $

TG Therapeutics (NASDAQ:TGTX) Trading Down 4.3%

Rafferty Asset Management LLC cut its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 33.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 571,126 shares of the biopharmaceutical company's stock after selling

Norges Bank bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,075,037 shares of the biopharmaceutical company's stock,

UBS Group AG grew its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 67.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 564,836 shares of the biopharmaceutical company's stock after buying an

Corient Private Wealth LLC boosted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 231.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 93,381 shares of the biopharmaceutical company's stock after acquiring an additional 65

BNP Paribas Financial Markets decreased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 74.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 293,607 shares of the biopharmac

TG Therapeutics (NASDAQ:TGTX) Stock Price Down 4.1%

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley decreased their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a research note issued to investors on Wednesday, May 1st. B. Riley analyst M. Mamtani now anticipates that the biopharma

HC Wainwright boosted their target price on TG Therapeutics from $45.00 to $49.00 and gave the stock a "buy" rating in a research report on Thursday.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The firm's quarterly revenue was up 713.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.28) EPS.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at B. Riley upped their Q2 2024 earnings estimates for shares of TG Therapeutics in a report issued on Tuesday, April 30th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings per s

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders acquired 13,983 call options on the company. This is an increase of 88% compared to the average daily volume of 7,433 call options.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at B. Riley cut their FY2026 earnings estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, April 30th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnin